Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 12/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30888599 | 1.00 | PKM (0.53) | PKMCA9KIF11NPC1MAPK13 | |
| SCHEMBL19260285 | 0.93 | PKM (0.56) | PKMCA9KIF11NPC1MAPK13 | |
| SCHEMBL19278654 | 0.85 | CA9 (0.52) | PKMCA9KIF11NPC1MAPK13 | |
| SCHEMBL4104017 | 0.85 | CA9 (0.52) | PKMCA9KIF11NPC1MAPK13 | |
| SCHEMBL222332 | 0.84 | AHR (0.53) | PKMKIF11 | |
| SCHEMBL7377454 | 0.79 | CA9 (0.54) | PKMCA9KIF11NPC1MAPK13 | |
| SCHEMBL522090 | 0.79 | CA9 (0.54) | PKMCA9KIF11NPC1MAPK13 | |
| SCHEMBL18112918 | 0.79 | CA9 (0.46) | PKMCA9KIF11NPC1MAPK13 | |
| SCHEMBL14778943 | 0.79 | PKM (0.50) | PKMCA9KIF11NPC1MAPK13 | |
| SCHEMBL2411213 | 0.79 | CYP19A1 (0.48) | PKMCA9KIF11NPC1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630403-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2025-10-15 | — | — | EP | disclosed |
| EP-3416633-B1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | UNIV ILLINOIS (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024121129-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2024-06-13 | — | — | WO | disclosed |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3416633-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | The Board of Trustees of the University of Illinois (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017142883-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017142883-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-08-24 | — | — | WO | disclosed |
| US-20080139546-A1 | Tetrahydroquinoline, indoline, and related aniline derivatives of heterocycle-fused benzodioxan methylamines | WYETH (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008042735-A1 | TETRAHYDROQUINOLINE, INDOLINE, AND RELATED ANILINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH (US) | 2008-04-10 | — | — | WO | disclosed |
| US-5053509-A | Microbiocides; AIDS | LABORATOIRE ROGER BELLON (FR) | 1991-10-01 | — | — | US | disclosed |
| US-5004745-A | Benzo[1,8]naphthyridine derivatives, their preparation and the compositions which contain them | LABORATOIRE ROGER BELLON (FR) | 1991-04-02 | — | — | US | disclosed |
| US-4990515-A | Chemical intermediates | RHONE-POULENC SANTE (FR) | 1991-02-05 | — | — | US | disclosed |
| US-4970213-A | Benzo(1,8)naphthyridine derivatives as intermediates | RHONE-POULENC SANTE (FR) | 1990-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC5, HDAC7 | PKM 3014/4885CA9 2142/4885KIF11 2305/4885 |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | HDAC1, HDAC5, HDAC7 | PKM 3014/4885CA9 2142/4885KIF11 2305/4885 |
| US-20080139546-A1 | Tetrahydroquinoline, indoline, and related aniline derivatives of heterocycle-fused benzodioxan methylamines | HTR5A, HTR2C, HTR3A | PKM 2824/4885CA9 4824/4885KIF11 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.